問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Nuclear Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Neurology

Division of Radiology

更新時間：2023-09-19

顏若芳YEN, RUOH-FANG
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

顏若芳

List

38Cases

2018-08-01 - 2023-07-31

IIT

Others

Investigation of post-stroke neurogenesis using rodent models and patients

  • Condition/Disease

    post-stroke

  • Test Drug

    18F-FLT

Participate Sites
2Sites

Recruiting2Sites

2020-08-01 - 2023-12-31

IIT

Others

Interactive Effects of Climate and Air Pollution on Cognitive Function and Neurodegeneration in the Elderly

  • Condition/Disease

    Dementia

  • Test Drug

    11C-PiB

Participate Sites
2Sites

Recruiting2Sites

2014-08-01 - 2019-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2012-08-01 - 2015-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2011-08-01 - 2013-07-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2011-06-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2016-12-31 - 2023-12-31

Phase III

A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease

  • Condition/Disease

    Prodromal Alzheimer's Disease

  • Test Drug

    Solanezumab (LY2062430)

Participate Sites
10Sites

Terminated9Sites

2017-06-01 - 2019-12-31

Phase III

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    Elenbecestat (E2609)

Participate Sites
13Sites

Terminated11Sites

胡朝榮
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

劉景寬
Kaohsiung Municipal Gangshan Hospital

未分科

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB